Neuronetics prices $30M public offering, shares slide 13% (STIM:NASDAQ)

Neuronetics (STIM) priced a public offering of 18.75M shares at $1.60 each, expecting ~$30M in gross proceeds. Its shares fell 13% in extended trading. The company also granted underwriters a 30-day option to purchase additional shares.

Original reporting
Published Nov 11, 2026, 7:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 7:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$STIM
Bearish
high confidence
Mentioned
$STIM
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$STIMBearishHigh
01

Why it matters

The dilution and capital raise triggered a 13% drop in extended trading, indicating market concern over share dilution and financing needs.

02

Market read

The offering is a material corporate action for a small‑cap biotech, creating short‑term trading opportunities.

03

What to watch

Potential strategic partnership or pipeline progress not disclosed in the brief.

Relevance 7/10Novelty 8/10Timing: after-hours reaction

Background

Neuronetics announced a secondary public offering to raise roughly $30M, pricing shares at $1.60 each.

Company-level read

Ticker impact

$STIMBearishHigh confidence
Context

Neuronetics shares fell 13% in extended trading after pricing a $30M public offering at $1.60 per share.

Expected impact

likely continued downside pressure as the market prices in dilution.

Evidence & confidence

Immediate 13% drop and a sizable dilution event suggest traders will stay cautious on the stock.

Market effects

May raise concerns for other small‑cap neuro‑technology firms about financing conditions.

Limited to U.S. markets; no broader regional effect.

Minimal global impact beyond niche investors.

Counterpoint

If the capital raise funds a breakthrough product, the stock could rebound once milestones are met.

Key entities

  • Neuronetics

    Neurostimulation device maker listed on NASDAQ under ticker STIM.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.